TRUQAP (capivasertib), FDA Approved for the Treatment of Breast Cancer, Available at Biologics by McKesson
CARY, N.C., Dec. 1, 2023 —Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare diseases, was selected by AstraZeneca as a specialty pharmacy provider for TRUQAPTM (capivasertib). TRUQAP, which was approved by the U.S. Food and Drug Administration (FDA) on Nov. 17...
Source: McKesson News - Category: Information Technology Source Type: news
More News: AstraZeneca | Breast Cancer | Cancer | Cancer & Oncology | Food and Drug Administration (FDA) | Information Technology | Rare Diseases